NATCO PHARMA has announced its results for the quarter ended June 2019. Here is a detailed performance review of the same:
No. of Mths Qtr. Ending | 3 Jun-18* | 3 Mar-19* | 3 Jun-19* | QoQ Change | YoY Change | |
---|---|---|---|---|---|---|
Net Sales | Rs m | 5,386 | 4,557 | 4,923 | 8.0% | -8.6% |
Other income | Rs m | 359 | 310 | 210 | -32.3% | -41.5% |
Turnover | Rs m | 5,745 | 4,867 | 5,133 | 5.5% | -10.7% |
Expenses | Rs m | 3,210 | 3,074 | 3,010 | -2.1% | -6.2% |
Gross profit | Rs m | 2,176 | 1,483 | 1,913 | 29.0% | -12.1% |
Depreciation | Rs m | 184 | 217 | 220 | 1.4% | 19.6% |
Interest | Rs m | 28 | 52 | 65 | 25.0% | 132.1% |
Profit before tax | Rs m | 2,323 | 1,524 | 1,838 | 20.6% | -20.9% |
Tax | Rs m | 512 | 320 | 410 | 28.1% | -19.9% |
Profit after tax | Rs m | 1,811 | 1,204 | 1,428 | 18.6% | -21.1% |
Gross profit margin | % | 40.4 | 32.5 | 38.9 | ||
Effective tax rate | % | 22.0 | 21.0 | 22.3 | ||
Net profit margin | % | 31.5 | 24.7 | 27.8 |
To see how NATCO PHARMA has performed over the last eight quarters,please visit here.
Over the last one year,NATCO PHARMA share price has moved down from Rs 768.0 to Rs 546.4, registering a Loss of Rs 221.6 or around 28.9%.
Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 12,722.2 (up 0.2%). Over the last one year it has moved down from 14,332.1 to 12,722.2, a gain of 1,610 points (down 11.2%).
Overall, the S&P BSE SENSEX is down 1.3% over the year.
At the current price of Rs 546.4, the price to earnings (P/E) ratio of NATCO PHARMA stands at 15.0 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 3.0 times.
For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More
| |
Equitymaster requests your view! Post a comment on "NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!